Stuart Fischer, MD, FACC, FACP, FSCAI, CCDS

Cardiovascular Diseases, Interventional Cardiology, Endovascular Diseases

• Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology
  National Board of Physicians and Surgeons
  2015-2017
• Certified in Interventional Cardiology
  American Board of Internal Medicine
  1999  (Recertification 2011 – 2021)
• Certified Cardiac Device Specialist (CCDS)
  International Board of Heart Rhythm Examiners (IBHRE)
  Certification Examination for Competency in Cardiac Rhythm Device Therapy for the Physician
  1988
• Certified in Cardiovascular Disease
  American Board of Internal Medicine
  1985
• Certified in Internal Medicine
  American Board of Internal Medicine
  1982

• Los Alamitos Medical Center
  3751 Katella Avenue
  Los Alamitos, California 90720
• MemorialCare Health System
  Long Beach Memorial Medical Center
  2801 Atlantic Avenue
  Long Beach, California 90801
• Lakewood Regional Medical Center
  3700 South Street
  Lakewood, California 90712

Los Alamitos Medical Center

• Chairman, Credentials Committee, 1996 – Present
• Member, Governing Board: 1994 – 2001, 2004 – Present
• Chief of Staff, 1994 – 1995
• Vice Chief of Staff, 1993
• Chairman, Quality Assurance Committee, 1993
• Chairman, Critical Care Committee, 1989
• Chairman, Department of Medicine, 1990 – 1992
• Member, Executive Committee, 1989 – Present
• Director Cardiac Catheterization Lab, 1989 – 2013
• Director, Pacemaker Clinic, 1985 – 2007
• Director, Echocardiography Lab, 1985 – 1997
• Secretary-Treasurer Medical Staff, 1992

Long Beach Memorial Medical Center

• Member, Interventional Cardiology Sub-Committee, 1997 – Present
• Member, Cardiology Credentials and QA Committee, 1996 – Present

Lakewood Regional Medical Center

• Member, Executive Committee: 2000 – 2001, 2004 – 2007
• Director, Cardiac Catheterization Lab, 2002 – 2005

• American College of Cardiology (FACC)
  Fellow
• American College of Physicians (FACP)
  Fellow
• The Society for Cardiac Angiography and Interventions (FSCAI)
  Fellow
• Heart Rhythm Society-IBHRE CCDS
  Member
• The Society of Geriatric Cardiology (FSGC)
  Fellow

• Co-Director Interventional Fellowship Program
  University of California, Irvine/Long Beach Memorial Hospital
  July 2000 – Present
• Assistant Clinical Professor of Medicine
  University of California, Irvine
  July 1989 – Present

• Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.
  Cardiologist
  Los Alamitos, California
  1985 – Present
• Fischer Mangold Group
  Emergency Medicine
  St. Francis – St. George Hospital
  Cincinnati, Ohio
  1982 – 1983
• Medical Health Service
  Staffing Three Cincinnati ER’s(Part Time)
  Cincinnati, Ohio
  1980 – 1983
• Bethesda Hospital
  Critical Care Physician (Part Time)
  Cincinnati, Ohio
  1981 – 1983

• American Medical Association Physician’s Recognition Award in Continuing Medical Education
  January 2008 – January 2011
• Sarah Lipson Seigal Memorial Award for Research
  1973

• Kumar P, Agarwal P, VanNatta B, Shandling A, Fischer S, McAtee P, Messenger J. “Clinical evaluation of ThinLine II (models 430-25 and 438-25 Intermedics) bipolar pacing leads.” PACE. 1999; 22 Part II 869.
• Dabestani A, Takenaka K, Allen B, Gardin J, Fischer S, Russell D, Henry W. “Effects of Spontaneous Respiration on Diastolic Left Ventricular Filling Assessed by Pulsed Doppler Echocardiography.” Am J Cardiol. 1988; 61:1356-1358.

• Cardiovascular Diseases Fellowship
  University of California, Irvine
  Division of Cardiology
  Orange, California
  Walter L. Henry, MD, Chief
  1983 – 1985
• Internal Medicine Residency
  University of Cincinnati Medical Center
  Department of Internal Medicine
  Cincinnati, Ohio
  Martin Goldberg, MD, Chair
  1980 – 1982
• Straight Medical Internship
  University of Cincinnati Medical Center
  Department of Internal Medicine
  Cincinnati, Ohio
  Martin Goldberg, MD, Chair
  1979 – 1980
• Medical Education
  Cornell University Medical College
  New York, New York
  1977 – 1979
• Medical Education
  Universita di Sassari
  Faculta di Medicinav
  Sassari, Italy
  1973 – 1977
• Undergraduate Education
  Brooklyn College
  Brooklyn, New York
  BS, Biology, 1969 – 1973

• Non-Invasive Cardiology:
  Echocardiography – TEE, Dobutamine and Stress Echo.
• Invasive-Interventional Cardiovascular and Endovascular Diseases:
  Catheterization, PTCA, Atherectomy, Stents, Laser Atherectomy, VBT, Pacing, Peripheral Vascular Disease, Peripheral Interventions, and Current Level II certification for performing and interpreting MDCTA

• AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
  Sub-Investigator | 2019
  Sponsor: CSL Behring LLC
  NCT03473223: https://clinicaltrials.gov/ct2/show/NCT03473223
• COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
  Principal Investigator | 2018 – Present
  Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  NCT03196349: https://clinicaltrials.gov/ct2/show/NCT03196349
• NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03464019: https://clinicaltrials.gov/ct2/show/NCT03464019
• NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03635996: https://clinicaltrials.gov/ct2/show/NCT03635996
• PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
  Sub-Investigator | 2018 – Present
  Sponsor: Novartis
  NCT02924727: https://clinicaltrials.gov/ct2/show/NCT02924727
• PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
  Principal Investigator | 2018 – Present
  Sponsor: Eko Devices
• GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  Principal Investigator | 2017 – Present
  Sponsor: Amgen
  NCT02929329 | https://clinicaltrials.gov/ct2/show/NCT02929329
• PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
  Sub-Investigator | 2017 – 2019
  Sponsor: Novartis
  NCT02887183 | https://clinicaltrials.gov/ct2/show/NCT02887183
• Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
  Principal Investigator | 2016 – Present
  Sponsor: CVRx, Inc.
  NCT02627196 | https://clinicaltrials.gov/show/NCT02627196
• MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
  Principal Investigator | 2016 – 2017
  Sponsor: Gilead/ICON
• THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
  Sub-Investigator | 2015 – Present
  Sponsor: AstraZeneca
  NCT01991795 | https://clinicaltrials.gov/show/NCT01991795
• Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
  Sub-Investigator | 2015 – 2016
  Sponsor: Amgen, Evidera
• DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
  Principal Investigator | 2013 – 2018
  Sponsor: AstraZeneca
  NCT01730534 | https://clinicaltrials.gov/ct2/show/NCT01730534
• ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  Sub-Investigator | 2013 – 2017
  Sponsor: Sanofi
  NCT01663402 | https://clinicaltrials.gov/ct2/show/NCT01663402
• SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
  Sub-Investigator | 2013 – 2017
  Sponsor: Yale University School of Medicine/NIH
  NCT01755052 | https://clinicaltrials.gov/ct2/show/NCT01755052
• RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
  Principal Investigator | 2013 – 2014
  Sponsor: Janssen Scientific Affairs/Johnson & Johnson
• Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
  Principal Investigator | 2013
  Sponsor: Tasly Pharmaceuticals
  NCT0169580 | https://clinicaltrials.gov/ct2/show/NCT01659580
• Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
  Principal Investigator | 2013 – 2018
  Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  NCT01594333 | https://clinicaltrials.gov/ct2/show/NCT01594333
• User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2PT/INR Monitoring System (ADAPT) BSTE-0159.
  Principal Investigator | 2012
  Sponsor: Alere San Diego
• Mission® PT Coagulation Monitoring System Clinical Study.
  Sub-Investigator | 2012
  Sponsor: ACON Laboratories, INC.
• The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
  Principal Investigator | 2012 – 2015
  Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
  NCT00786474 | https://clinicaltrials.gov/ct2/show/NCT00786474
• GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
  Principal Investigator | 2012 – Present
  Sponsor: Boehringer Ingelheim
  NCT01468701 | https://clinicaltrials.gov/ct2/show/NCT01468701
• California State Elective Percutaneous Coronary Intervention Pilot Program
  Principal Investigator | 2010 – 2014
• BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
  Sub-Investigator | 2010 – 2012
  Sponsor: St. Jude Medical Center
  NCT01062126 | https://clinicaltrials.gov/ct2/show/NCT01062126
• The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
  Principal Investigator | 2010 – 2014
  Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
  NCT01174550 | https://clinicaltrials.gov/ct2/show/NCT01174550
• ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
  Principal Investigator | 2010 – 2017
  Sponsor: Janssen Scientific Affairs, LLC
  Collaborator: Duke Clinical Research
  NCT01165710 | https://clinicaltrials.gov/ct2/show/NCT01165710
  NCT01701817 | https://clinicaltrials.gov/ct2/show/NCT01701817
• RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
  Sub-Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00837798 | https://clinicaltrials.gov/ct2/show/NCT00837798
• FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
  Sub-Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00418314 | http://clinicaltrials.gov/ct2/show/NCT00418314
• ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
  Principal Investigator | 2009 – 2015
  Sponsor: Daiichi Sankyo Pharma Development
  NCT00781391 | http://clinicaltrials.gov/ct2/show/NCT00781391
• Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE).
  Principal Investigator | 2008 – 2012
  Sponsor: F.Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development.
  NCT01323153 | https://clinicaltrials.gov/ct2/show/NCT01323153
• Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent.
  Sub-Investigator | 2007 – 2009
  Sponsor: Luitpold Pharmaceuticals, Inc.
  NCT00704028 | https://clinicaltrials.gov/ct2/show/NCT00704028
• Echocardiographic Assessment of Mitral Stenosis, Two-Dimensional Echocardiography versus Doppler Pressure Half Time
  Exercise Echocardiography in Coronary Artery Disease
  Doppler Mitral Flow in Various Pathologic States
  Thin-Line Bi-Polar Pacemaker Leads.
  Department of Physiology, Albany Medical College
  Sponsor: Intermedics

California, New York, Ohio

Rotary 1986 – 1989